Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

By Lee Yoo  

International Journal of Hematology, Vol. 97, Iss. 6, 2013-06 ,pp. : 804-807

Springer Publishing Company

Access to resources Recommend Favorite

Different involvement of the megakaryocytic lineage by the JAK2^V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis

By Hussein Kais   Brakensiek Kai   Buesche Guntram   Buhr Thomas   Wiese Birgitt   Kreipe Hans   Bock Oliver  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 245-253

Springer Publishing Company

Access to resources Recommend Favorite

JAK2^V617F positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature

By Michiels J.   Commandeur S.   Hoogenboom G.   Wegman J.   Scholten L.   Rijssel R.   Raeve H.  

Annals of Hematology, Vol. 86, Iss. 11, 2007-11 ,pp. : 793-800

Springer Publishing Company

Access to resources Recommend Favorite

Primary thrombophilia in México VII: the V617F mutation of JAK2 is not a frequent cause of thrombosis

By Garcés-Eisele Javier   González-Carrillo Martha L.   Reyes-Núñez Virginia   Ruiz-Argüelles Guillermo J.  

Hematology, Vol. 13, Iss. 4, 2008-08 ,pp. : 244-246

Maney Publishing

Access to resources Recommend Favorite

High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden

By Larsen Thomas Stauffer   Pallisgaard Niels   Møller Michael Boe   Hasselbalch Hans Carl  

Hematology, Vol. 13, Iss. 2, 2008-04 ,pp. : 71-76

Maney Publishing

Access to resources Recommend Favorite